217 related articles for article (PubMed ID: 15827447)
1. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
Aliment Pharmacol Ther; 2002 Jan; 16(1):159-65. PubMed ID: 11856091
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
5. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
6. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Eissele R; Brunner G; Simon B; Solcia E; Arnold R
Gastroenterology; 1997 Mar; 112(3):707-17. PubMed ID: 9041231
[TBL] [Abstract][Full Text] [Related]
7. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Kuipers EJ; Nelis GF; Klinkenberg-Knol EC; Snel P; Goldfain D; Kolkman JJ; Festen HP; Dent J; Zeitoun P; Havu N; Lamm M; Walan A
Gut; 2004 Jan; 53(1):12-20. PubMed ID: 14684569
[TBL] [Abstract][Full Text] [Related]
8. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
10. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Stolte M; Meining A; Schmitz JM; Alexandridis T; Seifert E
Aliment Pharmacol Ther; 1998 Mar; 12(3):247-53. PubMed ID: 9570259
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
Williams MP; Sercombe J; Hamilton MI; Pounder RE
Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
[TBL] [Abstract][Full Text] [Related]
12. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
13. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
14. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Geboes K; Dekker W; Mulder CJ; Nusteling K;
Aliment Pharmacol Ther; 2001 Nov; 15(11):1819-26. PubMed ID: 11683696
[TBL] [Abstract][Full Text] [Related]
15. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
16. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study.
Kyzekova J; Mour J
Hepatogastroenterology; 1999; 46(27):2048-56. PubMed ID: 10430396
[TBL] [Abstract][Full Text] [Related]
17. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
Moayyedi P; Wason C; Peacock R; Walan A; Bardhan K; Axon AT; Dixon MF
Helicobacter; 2000 Dec; 5(4):206-14. PubMed ID: 11179985
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
[TBL] [Abstract][Full Text] [Related]
19. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
